Last reviewed · How we verify
Durata Therapeutics Inc., an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Vancomycin / Linezolid | Vancomycin / Linezolid | phase 3 | glycopeptide antibiotic / oxazolidinone | D-alanyl-D-alanine terminus of cell wall precursors / 50S ribosomal subunit | Infectious Disease | |
| IV Dalbavancin | IV Dalbavancin | phase 3 | Lipoglycopeptide antibiotic | D-Ala-D-Ala peptidoglycan precursors | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Melinta Therapeutics, Inc. · 1 shared drug class
- University of Colorado, Denver · 1 shared drug class
- University of Pennsylvania · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Durata Therapeutics Inc., an affiliate of Allergan plc:
- Durata Therapeutics Inc., an affiliate of Allergan plc pipeline updates — RSS
- Durata Therapeutics Inc., an affiliate of Allergan plc pipeline updates — Atom
- Durata Therapeutics Inc., an affiliate of Allergan plc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Durata Therapeutics Inc., an affiliate of Allergan plc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/durata-therapeutics-inc-an-affiliate-of-allergan-plc. Accessed 2026-05-18.